Study title: Safety of four acellular pertussis combination vaccines (Infantrix-IPV, Boostrix, Covaxis and repevax) given a booster dose to six-year-old Finnish children
| Type of medicine: Non-centrally authorised vaccines | |||||
| Therapeutic area: Virus Diseases [C02] | |||||
| Brands: | |||||
| MAH holders: | |||||
| Assessment: | |||||
| Active substance: purif tetan toxoid,purif dipht toxoid,purif pert toxoid,purif filamentous haemaggl,purif fimbriae (agglutinogens 2 & 3),purif pertactin (69kda membrane protein)-inact polio vacc | |||||
| ATC code: J07CA02 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: S01-Td5/Td5I-407 (Perboo) | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |